Main content

    Melanoma Clinical Trials

    CPMC Cancer ServicesOpens new window | CPMC Center for Melanoma Research and TreatmentOpens new window


    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab
    Description: This is a Phase 2a, open-label, parallel group, partly randomized dose escalation trial to assess the safety and efficacy of a low dose, an intermediate dose, and high dose MSB0010445 given by intravenous infusion to subjects with advanced (unresectable or metastatic) melanoma in combination with stereotactic body radiation therapy (SBRT)
    Investigator: David R. Minor, MD
    Eligibility: Subjects, 18 y/o and older, with advanced unresectable or metastatic melanoma, previously treated with ipilimumab; with at least 1 lesion that can be irradiated
    Status: Active and open to enrollment
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study EMR 062235-005

    Title: A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
    Description: A study to compare the efficacy of MEK162 versus dacarbazine in patients with advanced unresectable or metastatic NRAS mutation-positive melanoma
    Investigator: David R. Minor, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed diagnosis of malignant melanoma
    Status: Active and open to enrollment
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study NEMO, MEK162A

    Title: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
    Description: A Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
    Investigator: David R. Minor, MD
    Eligibility: Male and female subjects, 18 y/o and older, who have histologically confirmed cutaneous metastatic melanoma
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study GSK 117277

    Title: Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Previously Untreated, Unresectable, Stage IIIb-IV Melanoma
    Description: Ipilimumab With or Without Talimogene Laherparepvec in Unresectable Melanoma
    Investigator (CPMC): David R. Minor, MD
    Investigator (Santa Rosa): Peter Brett, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed diagnosis of malignant melanoma
    Status: Active and open to enrollment
    Contact (CPMC): Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study Amgen TVEC
    Contact (Santa Rosa): Christina DeVisser, 707-576-4739, Email: DevissC@cpmcri.org about Study Amgen TVEC

    Title: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
    Description: A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection
    Investigator: David R. Minor, MD
    Eligibility: Male & female subjects, 18 y/o and older, with a completely resected histologically confirmed high-risk Stage IIIa, IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory
    Status: Acitve and open to enrollment
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study GSK 115532

    Title: Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
    Description: Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma
    Investigator: David R. Minor, MD
    Eligibility: Subjects, 18 y/o and older, who have Histologically confirmed cutaneous melanoma that is either Stage IIIc (unresectable) or Stage IV (metastatic)
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study GSK 115984

    Title: A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
    Description: A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
    Eligibility: Subjects, 18 y/o and older. Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST 1.1 criteria for solid tumors
    Investigator: Kevin Kim, MD
    Status: Coming soon
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study Novartis CMEK162X2114

    Title: Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma
    Description: The purpose of this study is to provide treatment with Nivolumab in combination with Ipilimumab and to assess the safety and tolerability of this combination in subjects who are anti-cytotoxic T lymphocyte associated antigen (CTLA)-4 treatment-naive and have unresectable or metastatic melanoma
    Eligibility: Subjects, 18 y/o and older with histologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer (AJCC) 2010 staging system, including mucosal melanoma
    Investigator: Kevin Kim, MD
    Status: Coming soon
    Contact: Ron Frianeza, 415-600-3027, Email: FrianeR@cpmcri.org about Study BMS CA209-218

    • updated October 2014

    Back to top